Potential Use of Patient-Specific Induced Pluripotent Stem Cell for Liver Fibrosis Thalassemia Treatment Management

Susanah, Susi and Widowati, Wahyu and Sari, Nur Melani and Revika, Revika and Kusuma, Hanna Sari Widya and Rizal, Rizal and Faried, Ahmad (2022) Potential Use of Patient-Specific Induced Pluripotent Stem Cell for Liver Fibrosis Thalassemia Treatment Management. Open Access Macedonian Journal of Medical Sciences., 10. ISSN 1857-9655

[img] Text
4.Int Publish 2022-4 (Susanah MJMS-Wahyu FKUKM).pdf

Download (944Kb)

Abstract

Thalassemia is the most common inherited single gene blood disease worldwide and present a significant health problem in the world. Approximately, 1.5% of the global populations (An estimated 80–90 million people) are carriers of β-thalassemia. Around 5% of Indonesia population is thought to carry the thalassemia gene. The globin imbalance in β-thalassemia major causes hemolysis and ineffective erythropoiesis which results in anemia leading to increases of iron absorption. Furthermore, repeated blood transfusion and long-term increased iron absorption will lead to excessive accumulation of iron in vital organs, especially in the liver, causes liver fibrosis then leading to liver disease. Iron overload can be controlled by iron chelating drugs with the risk of side effects; therefore, a breakthrough is needed. Stem cell technology has a potential to provide novel insight in thalassemia major, through induced pluripotent stem cells (iPSCs) who has the ability to differentiate into hepatic stellate cells (HSCs)-like cells. iPSCs derived HSC-like cells (iPSC-HSCs) present the phenotypic and functional characteristics of HSCs. The utilization of iPSCs is a new option in personalized thalassemia management.

Item Type: Article
Subjects: R Medicine > R Medicine (General)
Depositing User: Perpustakaan Maranatha
Date Deposited: 24 Mar 2022 08:53
Last Modified: 24 Mar 2022 08:53
URI: http://repository.maranatha.edu/id/eprint/30194

Actions (login required)

View Item View Item